Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms | Zendy

S J Ryan Arends | Zendy; Paul R. Rhomberg | Zendy; Nicole Cotroneo | Zendy; Aileen Rubio | Zendy; Robert K. Flamm | Zendy; Rodrigo E. Mendes | Zendy

Open Access

Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms

Author(s) -

S J Ryan Arends,

Paul R. Rhomberg,

Nicole Cotroneo,

Aileen Rubio,

Robert K. Flamm,

Rodrigo E. Mendes

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02618-18

Subject(s) - meropenem , klebsiella pneumoniae , proteus mirabilis , carbapenem , microbiology and biotechnology , broth microdilution , imipenem , antimicrobial , enterobacteriaceae , ertapenem , biology , escherichia coli , antibiotic resistance , minimum inhibitory concentration , antibiotics , gene , biochemistry

The antimicrobial activity of tebipenem and other carbapenem agents were testedin vitro against a set of recent clinical isolates responsible for urinary tract infection (UTI), as well as against a challenge set. Isolates were tested by reference broth microdilution and includedEscherichia coli (101 isolates),Klebsiella pneumoniae (208 isolates), andProteus mirabilis (103 isolates) species.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research